SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (66)4/4/2002 12:23:32 PM
From: keokalani'nui  Read Replies (2) of 146
 
Not much new at BoA conference, but there is a TPO slide showing increase in mean platelet count in mice over 3 doses. Looks like 5x at day 6 on max dose, tapering to baseline at day 14. Dose dependent response.

In answering question about comparison with Exanta, U'Pritchard said Exanta is a prodrug and its bioavailability is in the low teens, whereas 3dp's bioavailability is 85-95% producing less inter-patient blood level variation and consequently less risk of bleeding (of which they have seen 0 in models) and less monitoring. Also 3dp and JnJ believe that it will be a good once-a-day product--after alza's technology incorporated. Said azn publicly said Exanta will never be better than a 2x/day drug.

Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News